Christopher Nickas

Cooley advised Y-mAbs Therapeutics, a commercial-stage biopharmaceutical company focused on the development and commercialization of antibody-based therapeutics for the treatment of cancer, on its definitive merger agreement with SERB Pharmaceuticals. Under the agreement, SERB will acquire Y-mAbs, including its lead commercial oncology asset, DANYELZA, in an all-cash transaction representing an equity value of approximately $412 million.

Cooley advised the initial purchaser of GameStop in connection with GameStop’s offering of $2.25 billion aggregate principal amount of 0.00% convertible senior notes due 2032.

Cooley advised Renown Capital Partners, a venture capital firm that invests in early- and growth-stage companies globally with a focus on technologies that help secure efficient, affordable and reliable energy systems, as the lead investor in Utilidata’s $60.3 million Series C financing round. Partners Roy Moran, Dave Selden and John Clendenin led the Cooley team advising Renown Capital Partners.

Cooley advised Odeko, a mobile ordering and supply chain management software for coffee shops and cafés, on its $126 million Series E financing round. Lawyers Tamim Bazzi, Alex Abelson, Christopher Nickas and Sophie Kraff led the Cooley team advising Odeko.

Cooley advised long-time biotech client, Gamida Cell Ltd., and its wholly-owned subsidiary, Gamida Cell Inc. (collectively, the “Company”), in the Company’s global restructuring through a novel use of debt arrangement proceedings in Israel combined with Chapter 15 and 11 proceedings in the United States.